Artificial intelligence is increasingly integral to preclinical drug discovery, with new centers such as Mount Sinai’s AI Small Molecule Drug Discovery Center providing cross-sector research and training. Separately, Viome Life Sciences partnered with Microsoft to integrate AI-powered RNA molecular diagnostics into personalized nutrition and medicine, leveraging Azure cloud infrastructure for scalable data analysis. Startups are raising significant funds, and new software tools aim to harness AI for computational drug design and biomarker discovery, highlighting a growing AI investment frenzy within biotech and digital health sectors.